Case Study: “Challenges in the Development and Production of Live Virus Vaccines”
May 13, 2010 - The discovery and development of new and improved vaccines is critical for ensuring healthy populations. Charles River has consistently and effectively supported the vaccine industry for decades with its broad range of products and related services. Recently, we presented a case study titled ‘Challenges in the Development and Production of Live Virus Vaccines’ at the 2010 World Vaccine Congress, the longest-running and largest vaccine industry event in North America.
The case study touched on how the development and production of live viral vaccines is complicated by both the biological source and the biological nature of the product. Problems can arise at various stages, from the initial isolation to the growth, development and characterization of the master virus seed. Successful development requires scientists to apply their experience within established technology platforms and to work around problems with sensitivity to regulatory expectations. With broad expertise, contract research laboratory scientists can anticipate challenges, propose efficient solutions, identify cost-saving steps and accelerate development for vaccine clients. To illustrate, this case study describes the challenges arising from a cell-based approach for producing a live virus vaccine. To protect confidentiality, the case study was based on several actual vaccines produced and characterized for our clients.
To view the case study presentation, click here.
For more information on how we can support your vaccine development, contact us at askcharlesriver@crl.com or
1-877-CRIVER-1.
Related Information